

**ANNEX I**  
**SUMMARY OF PRODUCT CHARACTERISTICS**

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

## **1. NAME OF THE MEDICINAL PRODUCT**

Xospata 40 mg film-coated tablets

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each film-coated tablet contains 40 mg gilteritinib (as fumarate)

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Film-coated tablet (tablet).

Round, light yellow film-coated tablet, debossed with the company logo and '235' on the same side.

## **4. CLINICAL PARTICULARS**

### **4.1 Therapeutic indications**

Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation (see sections 4.2 and 5.1).

### **4.2 Posology and method of administration**

Treatment with Xospata should be initiated and supervised by a physician experienced in the use of anti-cancer therapies.

Before taking gilteritinib, relapsed or refractory AML patients must have confirmation of FMS-like tyrosine kinase 3 (FLT3) mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) using a validated test.

Xospata may be re-initiated in patients following haematopoietic stem cell transplantation (HSCT) (see Table 1).

#### Posology

The recommended starting dose is 120 mg gilteritinib (three 40 mg tablets) once daily.

Blood chemistries, including creatine phosphokinase, should be assessed prior to initiation of treatment, on day 15 and monthly for the duration of treatment.

An electrocardiogram (ECG) should be performed before initiation of gilteritinib treatment, on day 8 and 15 of cycle 1 and prior to the start of the next three subsequent months of treatment (see sections 4.4 and 4.8).

Treatment should continue until the patient is no longer clinically benefiting from Xospata or until unacceptable toxicity occurs. Response may be delayed; therefore, continuation of treatment at the prescribed dose for up to 6 months should be considered to allow time for a clinical response.

In the absence of a response [patient did not achieve a composite complete remission (CRc)] after 4 weeks of treatment, the dose can be increased to 200 mg (five 40 mg tablets) once daily, if tolerated or clinically warranted.

*Dose modifications*

**Table 1. Xospata dose interruption, reduction and discontinuation recommendations in patients with relapsed or refractory AML**

| Criteria   | Xospata dosing   |
|--|--|
| Differentiation syndrome   | <ul style="list-style-type: none"> <li>• If differentiation syndrome is suspected, administer corticosteroids and initiate hemodynamic monitoring (see section 4.4).</li> <li>• Interrupt gilteritinib if severe signs and/or symptoms persist for more than 48 hours after initiation of corticosteroids.</li> <li>• Resume gilteritinib at the same dose when signs and symptoms improve to Grade 2<sup>a</sup> or lower.</li> </ul> |
| Posterior reversible encephalopathy syndrome                                   | <ul style="list-style-type: none"> <li>• Discontinue gilteritinib.</li> </ul>  |
| QTcF interval >500 msec  | <ul style="list-style-type: none"> <li>• Interrupt gilteritinib.</li> <li>• Resume gilteritinib at a reduced dose (80 mg or 120 mg<sup>b</sup>) when QTcF interval returns to within 30 msec of baseline or ≤ 480 msec.</li> </ul>   |
| QTcF interval increased by >30 msec on ECG on day 8 of cycle 1                 | <ul style="list-style-type: none"> <li>• Confirm with ECG on day 9.</li> <li>• If confirmed, consider dose reduction to 80 mg.</li> </ul>  |
| Pancreatitis   | <ul style="list-style-type: none"> <li>• Interrupt gilteritinib until pancreatitis is resolved.</li> <li>• Resume treatment with gilteritinib at a reduced dose (80 mg or 120 mg<sup>b</sup>).</li> </ul>  |
| Other Grade 3 <sup>a</sup> or higher toxicity considered related to treatment. | <ul style="list-style-type: none"> <li>• Interrupt gilteritinib until toxicity resolves or improves to Grade 1<sup>a</sup>.</li> <li>• Resume treatment with gilteritinib at a reduced dose (80 mg or 120 mg<sup>b</sup>).</li> </ul>  |
| Planned HSCT   | <ul style="list-style-type: none"> <li>• Interrupt treatment with gilteritinib one week prior to administration of the conditioning regimen for HSCT.</li> <li>• Treatment can be resumed 30 days after HSCT if engraftment was successful, the patient did not have grade ≥2 acute graft versus host disease and was in CRc.<sup>c</sup></li> </ul>   |

a. Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, Grade 4 is life-threatening.

b. The daily dose can be reduced from 120 mg to 80 mg or from 200 mg to 120 mg.

c. CRc is defined as the remission rate of all CR (see section 5.1 for definition of CR), CRp [achieved CR except for incomplete platelet recovery (<100 x 10<sup>9</sup>/L)] and CRi (achieved all criteria for CR except for incomplete haematological recovery with residual neutropenia <1 x 10<sup>9</sup>/L with or without complete platelet recovery).

Xospata should be administered at about the same time each day. If a dose is missed or not taken at the usual time, the dose should be administered as soon as possible on the same day, and patients should return to the normal schedule the following day. If vomiting occurs after dosing, patients should not take another dose but should return to the normal schedule the following day.

### *Elderly*

No dose adjustment is required in patients  $\geq 65$  years of age (see section 5.2).

### *Hepatic impairment*

No dose adjustment is required for patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Xospata is not recommended for use in patients with severe (Child-Pugh Class C) hepatic impairment, as safety and efficacy have not been evaluated in this population (see section 5.2).

### *Renal impairment*

No dose adjustment is necessary in patients with mild or moderate renal impairment. There is no clinical experience in patients with severe renal impairment (see section 5.2).

### *Paediatric population*

The safety and efficacy of Xospata in children aged below 18 years has not yet been established. No data are available. Due to *in vitro* binding to 5HT<sub>2B</sub> (see section 4.5), there is a potential impact on cardiac development in patients less than 6 months of age.

### Method of administration

Xospata is for oral use.

The tablets can be taken with or without food. They should be swallowed whole with water and should not be broken or crushed.

## **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

## **4.4 Special warnings and precautions for use**

### Differentiation syndrome

Gilteritinib has been associated with differentiation syndrome (see section 4.8). Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells and may be life-threatening or fatal if not treated. Symptoms and clinical findings of differentiation syndrome include fever, dyspnoea, pleural effusion, pericardial effusion, pulmonary oedema, hypotension, rapid weight gain, peripheral oedema, rash, and renal dysfunction.

If differentiation syndrome is suspected, corticosteroid therapy should be initiated along with hemodynamic monitoring until symptom resolution. If severe signs and/or symptoms persist for more than 48 hours after initiation of corticosteroids, Xospata should be interrupted until signs and symptoms are no longer severe (see sections 4.2 and 4.8).

Corticosteroids can be tapered after resolution of symptoms and should be administered for a minimum of 3 days. Symptoms of differentiation syndrome may recur with premature discontinuation of corticosteroid treatment.

### Posterior reversible encephalopathy syndrome

There have been reports of posterior reversible encephalopathy syndrome (PRES) in patients receiving Xospata (see section 4.8). PRES is a rare, reversible, neurological disorder which can present with rapidly evolving symptoms including seizure, headache, confusion, visual and neurological disturbances, with or without associated hypertension and altered mental status. If PRES is suspected, it should be confirmed by brain imaging, preferably magnetic resonance imaging (MRI). Discontinuation of Xospata in patients who develop PRES is recommended (see sections 4.2 and 4.8).

### Prolonged QT interval

Gilteritinib has been associated with prolonged cardiac ventricular repolarisation (QT Interval) (see sections 4.8 and 5.1). QT prolongation can be observed in the first three months of treatment with

gilteritinib. Therefore, electrocardiogram (ECG) should be performed prior to initiation of treatment, on day 8 and 15 of cycle 1, and prior to the start of the next three subsequent months of treatment. Caution is warranted in patients with relevant cardiac history. Hypokalaemia or hypomagnesaemia may increase the QT prolongation risk. Hypokalaemia or hypomagnesaemia should therefore be corrected prior to and during Xospata treatment.

Xospata should be interrupted in patients who have a QTcF >500 msec (see section 4.2).

The decision to re-introduce gilteritinib treatment after an event of QT prolongation should be based on a careful consideration of benefits and risks. If Xospata is re-introduced at a reduced dose, ECG should be performed after 15 days of dosing, and prior to the start of the next three subsequent months of treatment. In clinical studies, 12 patients had QTcF >500 msec. Three patients interrupted and re-initiated treatment without recurrence of QT prolongation.

#### Pancreatitis

There have been reports of pancreatitis. Patients who develop signs and symptoms suggestive of pancreatitis should be evaluated and monitored. Xospata should be interrupted and can be resumed at a reduced dose when the signs and symptoms of pancreatitis have resolved (see section 4.2).

#### Interactions

Co-administration of CYP3A/P-gp inducers may lead to decreased gilteritinib exposure and consequently a risk for lack of efficacy. Therefore, concomitant use of gilteritinib with strong CYP3A4/P-gp inducers should be avoided (see section 4.5).

Caution is required when concomitantly prescribing gilteritinib with medicinal products that are strong inhibitors of CYP3A, P-gp and/or breast cancer resistant protein (BCRP) (such as, but not limited to, voriconazole, itraconazole, posaconazole and clarithromycin) because they can increase gilteritinib exposure. Alternative medicinal products that do not strongly inhibit CYP3A, P-gp and/or BCRP activity should be considered. In situations where satisfactory therapeutic alternatives do not exist, patients should be closely monitored for toxicities during administration of gilteritinib (see section 4.5).

Gilteritinib may reduce the effects of medicinal products that target 5HT<sub>2B</sub> receptor or sigma nonspecific receptors. Therefore, concomitant use of gilteritinib with these products should be avoided unless use is considered essential for the care of the patient (see section 4.5).

#### Embryofaetal toxicity and contraception

Pregnant women should be informed of the potential risk to a foetus (see sections 4.6 and 5.3). Females of reproductive potential should be advised to have a pregnancy test within seven days prior to starting treatment with Xospata and to use effective contraception during treatment with Xospata and for at least 6 months after stopping treatment. Women using hormonal contraceptives should add a barrier method of contraception. Males with female partners of reproductive potential should be advised to use effective contraception during treatment and for at least 4 months after the last dose of Xospata.

### **4.5 Interaction with other medicinal products and other forms of interaction**

Gilteritinib is primarily metabolised by CYP3A enzymes, which can be induced or inhibited by a number of concomitant medicinal products.

#### Effects of other medicinal products on Xospata

##### CYP3A/P-gp Inducers

Concomitant use of Xospata with strong CYP3A/P-gp inducers (e.g., phenytoin, rifampin and St. John's Wort) should be avoided because they can decrease gilteritinib plasma concentrations. In healthy subjects, co-administration of rifampicin (600 mg), a strong CYP3A/P-gp inducer, to steady state with a single 20 mg dose of gilteritinib decreased gilteritinib mean C<sub>max</sub> by 27% and mean AUC<sub>inf</sub>

by 70%, respectively, compared to subjects administered a single dose of gilteritinib alone (see section 4.4).

#### *CYP3A, P-gp and/or BCRP inhibitors*

Strong inhibitors of CYP3A, P-gp and/or BCRP (e.g., voriconazole, itraconazole, posaconazole, clarithromycin, erythromycin, captopril, carvedilol, ritonavir, azithromycin) can increase gilteritinib plasma concentrations. A single, 10 mg dose of gilteritinib co-administered with itraconazole (200 mg once daily for 28 days), a strong CYP3A, P-gp and BCRP inhibitor, to healthy subjects resulted in an approximate 20% increase in mean  $C_{max}$  and 2.2-fold increase in mean  $AUC_{inf}$  relative to subjects administered a single dose of gilteritinib alone. Gilteritinib exposure increased approximately 1.5-fold in patients with relapsed or refractory AML when co-administered with a strong CYP3A, P-gp and/or BCRP inhibitor (see section 4.4).

#### Effects of Xospata on other medicinal products

##### *Gilteritinib as an inhibitor or inducer*

Gilteritinib is not an inhibitor or inducer of CYP3A4 or an inhibitor of MATE1 *in vivo*. The pharmacokinetics of midazolam (a sensitive CYP3A4 substrate) were not significantly ( $C_{max}$  and AUC increased approximately 10%) affected after once-daily administration of gilteritinib (300 mg) for 15 days in patients with FLT3-mutated relapsed or refractory AML. Additionally, the pharmacokinetics of cephalexin (a sensitive MATE1 substrate) were not significantly ( $C_{max}$  and AUC decreased by less than 10%) affected after once daily administration of gilteritinib (200 mg) for 15 days in patients with FLT3-mutated relapsed or refractory AML.

Gilteritinib is an inhibitor of P-gp, BCRP and OCT1 *in vitro*. As no clinical data is available, it cannot be excluded that gilteritinib could inhibit these transporters at a therapeutic dose. Caution is advised during co-administration of gilteritinib with substrates of P-gp (e.g., digoxin, dabigatran etexilate), BCRP (e.g., mitoxantrone, methotrexate, rosuvastatin) and OCT1 (e.g., metformin).

##### *5HT<sub>2B</sub> receptor or sigma nonspecific receptor*

Based on *in vitro* data, gilteritinib may reduce the effects of medicinal products that target 5HT<sub>2B</sub> receptor or sigma nonspecific receptor (e.g., escitalopram, fluoxetine, sertraline). Avoid concomitant use of these medicinal products with Xospata unless use is considered essential for the care of the patient.

## **4.6 Fertility, pregnancy and lactation**

#### Women of childbearing potential / Contraception in males and females

Pregnancy testing is recommended for females of reproductive potential seven days prior to initiating Xospata treatment. Women of childbearing potential are recommended to use effective contraception (methods that result in less than 1% pregnancy rates) during and up to 6 months after treatment. It is unknown whether gilteritinib may reduce the effectiveness of hormonal contraceptives, and therefore women using hormonal contraceptives should add a barrier method of contraception. Males of reproductive potential should be advised to use effective contraception during treatment and for at least 4 months after the last dose of Xospata (see section 4.4).

#### Pregnancy

Gilteritinib can cause foetal harm when administered to pregnant women. There are no or limited amount of data from the use of gilteritinib in pregnant women. Reproductive studies in rats have shown that gilteritinib caused suppressed foetal growth, embryo-foetal deaths and teratogenicity (see section 5.3). Xospata is not recommended during pregnancy and in women of childbearing potential not using effective contraception.

#### Breast-feeding

It is unknown whether gilteritinib or its metabolites are excreted in human milk. Available animal data have shown excretion of gilteritinib and its metabolites in the animal milk of lactating rats and distribution to the tissues in infant rats via the milk (see section 5.3).

A risk to breast-fed children cannot be excluded. Breast-feeding should be discontinued during treatment with Xospata and for at least two months after the last dose.

#### Fertility

There are no data on the effect of gilteritinib on human fertility.

#### **4.7 Effects on ability to drive and use machines**

Gilteritinib has minor influence on the ability to drive and use machines. Dizziness has been reported in patients taking Xospata and should be considered when assessing a patient's ability to drive or use machines (see section 4.8).

#### **4.8 Undesirable effects**

##### Summary of the safety profile

The safety of Xospata was evaluated in 319 patients with relapsed or refractory AML who have received at least one dose of 120 mg gilteritinib.

The most frequent adverse reactions with gilteritinib were alanine aminotransferase (ALT) increased (82.1%), aspartate aminotransferase (AST) increased (80.6%), blood alkaline phosphatase increased (68.7%), blood creatine phosphokinase increased (53.9%), diarrhoea (35.1%), fatigue (30.4%), nausea (29.8%), constipation (28.2%), cough (28.2%), peripheral oedema (24.1%), dyspnea (24.1%), dizziness (20.4%), hypotension (17.2%), pain in extremity (14.7%), asthenia (13.8%), arthralgia (12.5%) and myalgia (12.5%).

The most frequent serious adverse reactions were acute kidney injury (6.6%), diarrhoea (4.7%), ALT increased (4.1%), dyspnea (3.4%), AST increased (3.1%) and hypotension (2.8%). Other clinically significant serious adverse reactions included differentiation syndrome (2.2%), electrocardiogram QT prolonged (0.9%) and posterior reversible encephalopathy syndrome (0.6%).

##### Tabulated list of adverse reactions

Adverse reactions observed during clinical studies are listed below by frequency category. Frequency categories are defined as follows: very common ( $\geq 1/10$ ); common ( $\geq 1/100$  to  $< 1/10$ ); uncommon ( $\geq 1/1,000$  to  $< 1/100$ ); rare ( $\geq 1/10,000$  to  $< 1/1,000$ ); very rare ( $< 1/10,000$ ); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

**Table 2: Adverse reactions**

| <b>Adverse drug reaction</b>                 | <b>All Grades %</b> | <b>Grades <math>\geq 3</math> %</b> | <b>Frequency category</b> |
|--|---------------------|-------------------------------------|---------------------------|
| <b>Immune system disorders</b>               |                     |                                     |                           |
| Anaphylactic reaction                        | 1.3                 | 1.3                                 | Common                    |
| <b>Nervous system disorders</b>              |                     |                                     |                           |
| Dizziness                                    | 20.4                | 0.3                                 | Very common               |
| Posterior reversible encephalopathy syndrome | 0.6                 | 0.6                                 | Uncommon                  |
| <b>Cardiac disorders</b>                     |                     |                                     |                           |
| Electrocardiogram QT prolonged               | 8.8                 | 2.5                                 | Common                    |
| Pericardial effusion                         | 4.1                 | 0.9                                 | Common                    |
| Pericarditis                                 | 1.6                 | 0                                   | Common                    |
| Cardiac failure                              | 1.3                 | 1.3                                 | Common                    |
| <b>Vascular disorders</b>                    |                     |                                     |                           |
| Hypotension                                  | 17.2                | 7.2                                 | Very common               |

| <b>Respiratory, thoracic and mediastinal disorders</b>      |      |      |             |
|---|------|------|-------------|
| Cough   | 28.2 | 0.3  | Very common |
| Dyspnoea  | 24.1 | 4.4  | Very common |
| Differentiation syndrome                                    | 3.4  | 2.2  | Common      |
| <b>Gastrointestinal disorders</b>                           |      |      |             |
| Diarrhoea   | 35.1 | 4.1  | Very common |
| Nausea  | 29.8 | 1.9  | Very common |
| Constipation  | 28.2 | 0.6  | Very common |
| <b>Hepatobiliary disorders</b>                              |      |      |             |
| Alanine aminotransferase increased*                         | 82.1 | 12.9 | Very common |
| Aspartate aminotransferase increased*                       | 80.6 | 10.3 | Very common |
| <b>Musculoskeletal and connective tissue disorders</b>      |      |      |             |
| Blood creatine phosphokinase increased*                     | 53.9 | 6.3  | Very common |
| Blood alkaline phosphatase increased*                       | 68.7 | 1.6  | Very common |
| Pain in extremity   | 14.7 | 0.6  | Very common |
| Arthralgia  | 12.5 | 1.3  | Very common |
| Myalgia   | 12.5 | 0.3  | Very common |
| Musculoskeletal pain  | 4.1  | 0.3  | Common      |
| <b>Renal and urinary disorders</b>                          |      |      |             |
| Acute kidney injury   | 6.6  | 2.2  | Common      |
| <b>General disorders and administration site conditions</b> |      |      |             |
| Fatigue   | 30.4 | 3.1  | Very common |
| Peripheral oedema   | 24.1 | 0.3  | Very common |
| Asthenia  | 13.8 | 2.5  | Very common |
| Malaise   | 4.4  | 0    | Common      |

\* Frequency is based on central laboratory values.

#### Description of selected adverse reactions

##### *Differentiation syndrome*

Of 319 patients treated with Xospata in the clinical studies, 11 (3%) experienced differentiation syndrome. Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells and may be life-threatening or fatal if not treated. Symptoms and clinical findings of differentiation syndrome in patients treated with Xospata included fever, dyspnoea, pleural effusion, pericardial effusion, pulmonary oedema, hypotension, rapid weight gain, peripheral oedema, rash, and renal dysfunction. Some cases had concomitant acute febrile neutrophilic dermatosis. Differentiation syndrome occurred as early as one day and up to 82 days after Xospata initiation and has been observed with or without concomitant leukocytosis. Of the 11 patients who experienced differentiation syndrome, 9 (82%) recovered after treatment or after dose interruption of Xospata. For recommendations in case of suspected differentiation syndrome see sections 4.2 and 4.4.

##### *PRES*

Of the 319 patients treated with Xospata in the clinical studies, 0.6% experienced posterior reversible encephalopathy syndrome (PRES). PRES is a rare, reversible, neurological disorder, which can present with rapidly evolving symptoms including seizure, headache, confusion, visual and neurological disturbances, with or without associated hypertension. Symptoms have resolved after discontinuation of treatment (see sections 4.2 and 4.4).

##### *QT prolongation*

Of the 317 patients treated with gilteritinib at 120 mg with a post-baseline QTC value in clinical studies, 4 patients (1%) experienced a QTcF >500 msec. Additionally, across all doses, 12 patients (2.3%) with relapsed/refractory AML had a maximum post-baseline QTcF interval >500 msec (see sections 4.2, 4.4 and 5.1).



#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](#).

### **4.9 Overdose**

There is no known specific antidote for Xospata. In the event of an overdose, treatment with Xospata should be stopped. Patients must be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic and supportive treatment initiated, taking into consideration the long half-life estimated at 113 hours.

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: antineoplastic agents, protein kinase inhibitors, ATC code: L01EX13

#### Mechanism of action

Gilteritinib fumarate is a FLT3 and AXL inhibitor.

Gilteritinib inhibits FLT3 receptor signalling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y, and it induces apoptosis in leukemic cells expressing FLT3-ITD.

#### Pharmacodynamic effects

In patients with relapsed or refractory AML receiving gilteritinib 120 mg, substantial (> 90%) inhibition of FLT3 phosphorylation was rapid (within 24 hours after first dose) and sustained, as characterised by an *ex vivo* plasma inhibitory activity (PIA) assay.

#### Prolonged QT interval

A concentration-related increase in change from baseline of QTcF was observed across gilteritinib doses ranging from 20 to 450 mg. The predicted mean change from baseline of QTcF at the mean steady-state  $C_{max}$  (282.0 ng/mL) at the 120 mg daily dose was 4.96 msec with an upper 1-sided 95% CI = 6.20 msec.

#### Clinical efficacy and safety

##### *Relapsed or refractory AML*

Efficacy and safety were evaluated in the active-controlled, phase 3 study (2215-CL-0301).

##### *ADMIRAL study (2215-CL-0301)*

The ADMIRAL study is a Phase 3, open-label, multicentre, randomised clinical study of adult patients with relapsed or refractory AML with a FLT3 mutation as determined by the LeukoStrat® CDx FLT3 Mutation Assay. In this study, 371 patients were randomised in a 2:1 ratio to receive gilteritinib or one of the following salvage chemotherapies (247 in the gilteritinib arm and 124 in the salvage chemotherapy arm):

- cytarabine 20 mg twice daily by subcutaneous injection (SC) or intravenous infusion (IV) for 10 days (days 1 through 10) (LoDAC)
- azacitidine 75 mg/m<sup>2</sup> once daily by SC or IV for 7 days (days 1 through 7)
- mitoxantrone 8 mg/m<sup>2</sup>, etoposide 100 mg/m<sup>2</sup> and cytarabine 1000 mg/m<sup>2</sup> once daily by IV for 5 days (days 1 through 5) (MEC)
- granulocyte colony-stimulating factor 300 mcg/m<sup>2</sup> once daily by SC for 5 days (days 1 to 5), fludarabine 30 mg/m<sup>2</sup> once daily by IV for 5 days (days 2 through 6), cytarabine 2000 mg/m<sup>2</sup> once daily by IV for 5 days (days 2 through 6), idarubicin 10 mg/m<sup>2</sup> once daily by IV for 3 days (days 2 through 4) (FLAG-Ida).

Patients included were relapsed or refractory after first line AML therapy and were stratified by response to prior AML treatment and preselected chemotherapy i.e. high or low intensity. While the study included patients with various AML-related cytogenetic abnormalities, patients with acute promyelocytic leukaemia (APL) or therapy-related AML were excluded.

Sixteen patients were randomised but not treated in the study (1 patient in the gilteritinib arm and 15 patients in the chemotherapy arm). Gilteritinib was given orally at a starting dose of 120 mg daily until unacceptable toxicity or lack of clinical benefit. Dose reductions were allowed, to manage adverse reactions, and dose increases were allowed, for those patients who did not respond at the starting dose of 120 mg.

Of the patients who were pre-selected to receive salvage chemotherapy, 60.5% were randomised to high intensity and 39.5% to low intensity. MEC and FLAG-Ida were given for up to two cycles depending on response to first cycle. LoDAC and azacitidine were given in continuous 4-week cycles until unacceptable toxicity or lack of clinical benefit.

The demographic and baseline characteristics were well-balanced between the two treatment arms. The median age at randomisation was 62 years (range 20 to 84 years) in the gilteritinib arm and 62 years (range 19 to 85 years) in the salvage chemotherapy arm. In the study 42% of patients were 65 years or older and 12% were 75 years or older. Fifty-four percent of the patients were female. Most patients in the study were Caucasian (59.3%); 27.5% Asian, 5.7% Black, 4% other races and 3.5% unknown. The majority of patients (83.8%) had an ECOG performance status score of 0 or 1. Patients had the following confirmed mutations: FLT3-ITD alone (88.4%), FLT3-TKD alone (8.4%) or both FLT3-ITD and FLT3-TKD (1.9%). Twelve percent of patients received previous treatment with another FLT3 inhibitor. A majority of patients had AML with intermediate risk cytogenetics (73%), 10% had unfavourable, 1.3% had favourable and 15.6% had unclassified cytogenetics.

Prior to treatment with gilteritinib, 39.4% of patients had primary refractory AML and the majority of these patients were classified as refractory after 1 cycle of chemotherapy induction treatment, 19.7% had relapsed AML after an allogeneic haematopoietic stem cell transplant (HSCT) and 41% had relapsed AML with no allogeneic HSCT.

The primary efficacy endpoint for the final analysis was OS in the intent-to-treat (ITT) population, measured from the date of randomisation until death by any cause (number of events analysed was 261). Patients randomised to the gilteritinib arm had significantly longer survival compared to the chemotherapy arm (HR 0.637; 95% CI 0.490 – 0.830; 1 sided p-value: 0.0004). The median OS was 9.3 months for patients receiving gilteritinib and 5.6 months for those receiving chemotherapy. Efficacy was further supported by the rate of complete remission (CR)/complete remission with partial haematologic recovery (CRh) (Table 3, Figure 1).


**Table 3: ADMIRAL study overall survival and complete remission in patients with relapsed or refractory AML**

|   | <b>Gilteritinib<br/>(N=247)</b> | <b>Chemotherapy<br/>(N=124)</b> |
|---|---------------------------------|---------------------------------|
| <b>Overall survival</b>                 |                                 |                                 |
| Deaths, n (%)                           | 171 (69.2)                      | 90 (72.6)                       |
| Median in months (95% CI)               | 9.3 (7.7, 10.7)                 | 5.6 (4.7, 7.3)                  |
| Hazard Ratio (95% CI)                   | 0.637 (0.490, 0.830)            |                                 |
| p-value (1-sided)                       | 0.0004                          |                                 |
| 1 year survival rate, % (95% CI)        | 37.1 (30.7, 43.6)               | 16.7 (9.9, 25)                  |
| <b>Complete remission</b>               |                                 |                                 |
| CR <sup>a</sup> (95% CI <sup>b</sup> )  | 21.1% (16.1, 26.7)              | 10.5% (5.7, 17.3)               |
| CRh <sup>c</sup> (95% CI <sup>b</sup> ) | 13% (9, 17.8)                   | 4.8% (1.8, 10.2)                |
| CR/CRh (95% CI <sup>b</sup> )           | 34% (28.1, 40.3)                | 15.3% (9.5, 22.9)               |

CI: confidence interval

- CR was defined as an absolute neutrophil count  $\geq 1.0 \times 10^9/L$ , platelets  $\geq 100 \times 10^9/L$ , normal marrow differential with  $<5\%$  blasts, must have been red blood cells, platelet transfusion independent and no evidence of extramedullary leukemia.
- The 95% CI rate was calculated using the exact method based on binomial distribution.
- CRh was defined as marrow blasts  $<5\%$ , partial haematologic recovery absolute neutrophil count  $\geq 0.5 \times 10^9/L$  and platelets  $\geq 50 \times 10^9/L$ , no evidence of extramedullary leukemia and could not have been classified as CR.

**Figure 1: Kaplan-Meier plot of overall survival in ADMIRAL study**



Number of Subjects At Risk

|              |     |     |     |     |    |    |    |    |    |   |   |   |   |
|--------------|-----|-----|-----|-----|----|----|----|----|----|---|---|---|---|
| Gilteritinib | 247 | 206 | 157 | 106 | 64 | 44 | 31 | 14 | 11 | 4 | 1 | 0 | 0 |
| Chemotherapy | 124 | 84  | 52  | 29  | 13 | 12 | 8  | 7  | 5  | 3 | 1 | 0 | 0 |

For patients who achieved a CR/CRh, the median time to first response was 3.7 months (range, 0.9 to 10.6 months) in the gilteritinib arm and 1.2 months (range: 1 to 2.6 months) in the salvage chemotherapy arm. The median time to best response of CR/CRh was 3.8 months (range, 0.9 to 16 months) in the gilteritinib arm and 1.2 months (range: 1 to 2.6 months) in the salvage chemotherapy arm.

#### *CHRYSALIS study (2215-CL-0101)*

The supportive Phase 1/2 dose-escalation study 2215-CL-0101 included 157 patients with FLT3 mutated AML treated with either 1 or  $>1$  prior lines of treatment in the combined dose group (i.e. 80 mg, 120 mg or 200 mg); 31.2% received 1 prior line of treatment and 68.8% received  $>1$  prior lines of treatment.

The response rate (CR/CRh) observed in Study 2215-CL-0101 in the patients who received more than 1 line of prior therapy was 21.4% and 15.7% for the 120 mg dose and the combined dose levels, respectively. The median OS was 7.2 months and 7.1 months for the 120 mg dose and the combined dose levels, respectively.

#### *Paediatric population*

The European Medicines Agency has deferred the obligation to submit the results of studies with Xospata in one or more subsets of the paediatric population in the treatment of acute myeloid leukaemia. See 4.2 for information on paediatric use.

## **5.2 Pharmacokinetic properties**

### Absorption

Following oral administration of gilteritinib, peak plasma concentrations are observed at a median  $t_{max}$  approximately between 4 and 6 hours in healthy volunteers and patients with relapsed or refractory AML. Gilteritinib undergoes first-order absorption with an estimated absorption rate ( $k_a$ ) of

0.43 h<sup>-1</sup> with a lag time of 0.34 hours based on population PK modelling. Median steady-state maximum concentration (C<sub>max</sub>) is 282.0 ng/mL (CV% = 50.8), and area under the plasma concentration curve during 24-hour dosing interval (AUC<sub>0-24</sub>) is 6180 ng·h/mL (CV% = 46.4) after once-daily dosing of 120 mg gilteritinib. Steady-state plasma levels are reached within 15 days of once-daily dosing with an approximate 10-fold accumulation.

#### *Effect of food*

In healthy adults, gilteritinib C<sub>max</sub> and AUC decreased by approximately 26% and less than 10%, respectively, when a single 40 mg dose of gilteritinib was co-administered with a high fat meal compared to gilteritinib exposure in fasted state. Median t<sub>max</sub> was delayed 2 hours when gilteritinib was administered with a high-fat meal.

#### Distribution

The population estimate of central and peripheral volume of distribution were 1092 L and 1100 L, respectively. These data indicate gilteritinib distributes extensively outside of plasma, which may indicate extensive tissue distribution. *In vivo* plasma protein binding in humans is approximately 90% and gilteritinib is primarily bound to albumin.

#### Biotransformation

Based on *in vitro* data, gilteritinib is primarily metabolised via CYP3A4. The primary metabolites in humans include M17 (formed via N-dealkylation and oxidation), M16 and M10 (both formed via N-dealkylation) and were observed in animals. None of these three metabolites exceeded 10% of overall parent exposure. The pharmacological activity of the metabolites against FLT3 and AXL receptors is unknown.

#### Transporter drug-drug interactions

*In vitro* experiments demonstrated that gilteritinib is a substrate of P-gp and BCRP. Gilteritinib may potentially inhibit BCRP, P-gp and OCT1 at clinically relevant concentrations (see section 4.5).

#### Elimination

After a single dose of [<sup>14</sup>C] -gilteritinib, gilteritinib is primarily excreted in faeces with 64.5% of the total administered dose recovered in faeces. Approximately 16.4% of the total dose was excreted in urine as unchanged drug and metabolites. Gilteritinib plasma concentrations declined in a bi-exponential manner with a population mean estimated half-life of 113 hours. The estimated apparent clearance (CL/F) based on the population PK model is 14.85 L/h.

#### Linearity/non-linearity

In general, gilteritinib exhibited linear, dose-proportional pharmacokinetics after single and multiple dose administration at doses ranging from 20 to 450 mg in patients with relapsed or refractory AML.

#### Special populations

A population pharmacokinetic analysis was performed to evaluate the impact of intrinsic and extrinsic covariates on the predicted exposure of gilteritinib in patients with relapsed or refractory AML. Covariate analysis indicated that age (20 years to 90 years), and body weight (36 kg to 157 kg) were statistically significant; however predicted change in gilteritinib exposure was less than 2-fold.

#### *Hepatic impairment*

The effect of hepatic impairment on gilteritinib pharmacokinetics was studied in subjects with mild (Child-Pugh Class A) and moderate (Child-Pugh Class B) hepatic impairment. Results indicate unbound gilteritinib exposure in subjects with mild or moderate hepatic impairment is comparable to that observed in subjects with normal hepatic function. The effect of mild hepatic impairment [as defined by NCI-ODWG] on gilteritinib exposure was also assessed using the population PK model and the results demonstrate little difference in predicted steady-state gilteritinib exposure relative to a typical patient with relapsed or refractory AML and normal liver function.

Gilteritinib has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).

### *Renal impairment*

A dedicated renal impairment study has not been conducted to assess of the effect of renal impairment on gilteritinib pharmacokinetics. The effect of mild or moderate renal impairment was evaluated using a population pharmacokinetic model. Serum creatinine, a marker of renal function, was identified as a statistically significant covariate. However, the predicted increase on gilteritinib exposure was less than 2-fold. The effect of severe renal impairment on gilteritinib exposure has not been investigated (see section 4.2).

### **5.3 Preclinical safety data**

Adverse reactions not observed in clinical studies, but seen in animals (safety pharmacology/repeat dose toxicity) at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows:

#### Safety pharmacology

In rats, decreased urination at 30 mg/kg and higher and decreased defecation at 100 mg/kg were observed. In dogs, positive faecal occult blood at 10 mg/kg and higher, a decrease in the blood calcium concentration at 30 mg/kg, and salivation and an increase followed by a decrease in the blood calcium concentration at 100 mg/kg were observed. These changes were observed at plasma exposure levels similar to or less than clinical exposure levels. A possible clinical relevance of these findings is unknown.

#### Repeat dose toxicity

In the repeated dose toxicity studies in rats and dogs, target organs of toxicity were the gastrointestinal tract (haemorrhage in dogs), lymphohaematopoietic system (lymphocyte necrosis and bone marrow hypocellularity with changes in haematological parameters), eye (inflammation and lens opacity in rats, fundus colour change in dogs, retinal vacuolation), lung (interstitial pneumonia in rats and inflammation in dogs), kidney (renal tubule changes with a positive urine occult blood reaction) and liver (hepatocyte vacuolation), urinary bladder (epithelial vacuolation), epithelial tissue (ulcer and inflammation), and phospholipidosis (lung and kidney in rats). These changes were observed at plasma exposure levels similar to or less than clinical exposure levels. Reversibility of most of the changes was indicated by the end of the 4-week recovery period. A possible clinical relevance of these findings is unknown.

#### Genotoxicity

Gilteritinib did not induce gene mutation or chromosomal aberrations *in vitro*. The *in vivo* micronucleus test showed that gilteritinib has a potential to induce micronuclei in mice.

#### Reproductive toxicity

Gilteritinib showed suppressed foetal growth, and induced embryo-foetal deaths and teratogenicity in the embryo-foetal development studies in rats at exposure levels similar to clinical exposure levels. Placental transfer of gilteritinib was shown in the rat resulting in transfer of radioactivity to the foetus similar to that observed in maternal plasma.

Gilteritinib was excreted into the milk of lactating rats with milk concentrations being higher than in maternal plasma. Gilteritinib was distributed through the breast milk to different tissues, except for the brain, of suckling rats.

#### Juvenile animal toxicity study

In the juvenile toxicity study in rats, the minimum lethal dose level (2.5 mg/kg/day) was much lower than that of adult rats (20 mg/kg/day). The gastrointestinal tract was identified as one of the target organs similar as in adult rats.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

#### Tablet core

Mannitol (E421)  
Hydroxypropylcellulose  
Hydroxypropylcellulose, low-substituted  
Magnesium stearate

#### Film-coating

Hypromellose  
Talc  
Macrogol  
Titanium dioxide  
Iron oxide yellow (E172)

### **6.2 Incompatibilities**

Not applicable

### **6.3 Shelf life**

4 years.

### **6.4 Special precautions for storage**

This medicinal product does not require any special temperature storage conditions. Store in the original package in order to protect from light.

### **6.5 Nature and contents of container**

OPA/aluminium/PVC/aluminium blisters containing 21 film-coated tablets.

Each pack contains 84 film-coated tablets.

### **6.6 Special precautions for disposal**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Astellas Pharma Europe B.V.  
Sylviusweg 62  
2333 BE Leiden  
The Netherlands

## **8. MARKETING AUTHORISATION NUMBER(S)**

EU/1/19/1399/001

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 24 October 2019

## **10. DATE OF REVISION OF THE TEXT**

Detailed information on this medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu>.

**ANNEX II**

- A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**
- D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**



## **A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**

### Name and address of the manufacturer responsible for batch release

Astellas Pharma Europe B.V.  
Sylviusweg 62  
2333 BE Leiden  
The Netherlands

## **B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## **C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

### **• Periodic safety update reports (PSURs)**

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder (MAH) shall submit the first PSUR for this product within 6 months following authorisation.

## **D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

### **• Risk management plan (RMP)**

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

### **• Additional risk minimisation measures**

Prior to the launch of Xospata in each Member State the MAH must agree about the content and format of the physician educational material, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority. The patient alert card will be integrated in the packaging and the content will be agreed as part of the labelling (Annex III).

The educational material is aimed at haematologists who treat patients with leukemias including AML, and patients with AML prescribed Xospata to further inform prescribers and patients regarding the important identified risk of differentiation syndrome.

The MAH shall ensure that in each Member State where Xospata is marketed, haematologists who are expected to prescribe Xospata, and patients who are expected to use Xospata are provided with the following educational materials:

- Physician educational material
- Patient Alert Card

Physician educational material:

- The Summary of Product Characteristics
- Educational tool targeting prescribers
  - Educational tool targeting prescribers:
    - Information on Xospata, including the approved indication according to the SmPC.
    - Description of the signs and symptoms of differentiation syndrome.
    - Management of differentiation syndrome.

The patient information pack:

- Patient information leaflet
- Patient alert card
  - Patient alert card:
    - Information for patients that Xospata treatment may cause differentiation syndrome.
    - Description of signs or symptoms of the safety concern and when to seek medical care if differentiation syndrome is suspected
    - A warning message for healthcare professionals treating the patient at any time, including in conditions of emergency, that the patient is using Xospata.
    - Contact details of the treating physician who has prescribed Xospata.
    - Needs to be carried all the time and presented to any healthcare professional.

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**OUTER CARTON WITH BLUE BOX**

**1. NAME OF THE MEDICINAL PRODUCT**

Xospata 40 mg film-coated tablets  
gilteritinib

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each film-coated tablet contains 40 mg gilteritinib (as fumarate).

**3. LIST OF EXCIPIENTS**

**4. PHARMACEUTICAL FORM AND CONTENTS**

84 film-coated tablets

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use  
Do not break or crush the tablets.  
Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Store in the original package in order to protect from light.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Astellas Pharma Europe B.V.  
Sylviusweg 62  
2333 BE Leiden  
The Netherlands

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/19/1399/001 84 film coated tablets

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

xospata 40 mg

**17. UNIQUE IDENTIFIER - 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC  
SN  
NN

**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

**BLISTER**

**1. NAME OF THE MEDICINAL PRODUCT**

Xospata 40 mg tablets  
gilteritinib

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

Astellas

**3. EXPIRY DATE**

EXP

**4. BATCH NUMBER**

Lot

**5. OTHER**

## CONTENT OF PATIENT ALERT CARD

### PATIENT ALERT CARD

#### XOSPATA (gilteritinib)

- Carry this card with you **at all times**, especially when you travel or when you see another doctor.
- Please ensure you show this card to any doctor, pharmacist or nurse for any medical treatment or at any visits to the hospital or clinic.
- Please contact your doctor **immediately**, if you develop any side effects, in particular those listed on this card.

### IMPORTANT SAFETY INFORMATION FOR PATIENTS

#### **Xospata may cause serious side effects, including differentiation syndrome.**

Differentiation syndrome is a condition that affects your blood cells and may be life-threatening or lead to death if not treated in a timely manner.

Talk to your doctor, pharmacist or nurse **immediately** if you have any of the following symptoms:

- Fever
- Trouble Breathing
- Rash
- Dizziness or lightheadedness
- Rapid weight gain
- Swelling of your arms or legs

Differentiation syndrome can happen any time during the first 3 months of treatment from as early as 1 day after starting treatment. Getting medical treatment early may stop the problem from becoming more serious.

Your doctor will monitor you, may pause your treatment and/or may give you a medicine to treat your condition.

If you have any further questions about your treatment, please contact your doctor.

### IMPORTANT INFORMATION FOR HEALTHCARE PROVIDERS

- This patient is being treated with Xospata (gilteritinib), which can cause differentiation syndrome.
- Symptoms include fever, dyspnoea, pleural effusion, pericardial effusion, pulmonary oedema, hypotension, rapid weight gain, peripheral oedema, rash, and renal dysfunction.
- If differentiation syndrome is suspected, corticosteroid therapy should be initiated along with hemodynamic monitoring until symptom resolution.
- If severe signs and/or symptoms persist for more than 48 hours after initiation of corticosteroids, Xospata should be interrupted until signs and symptoms are no longer severe.

Please contact the patient's Haematologist/Oncologist for more information and consult the Product Information for gilteritinib available at <https://www.ema.europa.eu/>.

**My name:** \_\_\_\_\_

**My contact number:** \_\_\_\_\_

**Emergency contact:** \_\_\_\_\_

**Emergency contact number:** \_\_\_\_\_

**Name of Haematologist/Oncologist/Oncology Nurse:** \_\_\_\_\_

**Contact number:** \_\_\_\_\_

**After-hours contact number:** \_\_\_\_\_

**Name of my Hospital:** \_\_\_\_\_

**My Hospital contact number:** \_\_\_\_\_



**B. PACKAGE LEAFLET**

## Package leaflet: Information for the patient

### Xospata 40 mg film-coated tablets gilteritinib

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

**Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

#### What is in this leaflet

1. What Xospata is and what it is used for
2. What you need to know before you take Xospata
3. How to take Xospata
4. Possible side effects
5. How to store Xospata
6. Contents of the pack and other information

#### 1. What Xospata is and what it is used for

##### What Xospata is

Xospata belongs to a class of cancer medicines called protein kinase inhibitors. It contains the active substance gilteritinib.

##### What Xospata is used for

Xospata is used to treat adults with acute myeloid leukaemia (AML), a cancer of certain white blood cells. Xospata is used if AML is linked to an alteration of a gene called FLT3, and is given to patients whose disease has come back or has not improved after previous treatment.

##### How Xospata works

In AML, patients develop large numbers of abnormal white blood cells. Gilteritinib blocks the action of certain enzymes (kinases) needed for the abnormal cells to multiply and grow, thus preventing the growth of the cancer.

#### 2. What you need to know before you take Xospata

##### Do not take Xospata

- if you are allergic to gilteritinib or any of the other ingredients of this medicine (listed in section 6).

##### Warnings and precautions

Talk to your doctor, pharmacist or nurse straight away:

- if you have any of the following symptoms: fever, trouble breathing, rash, dizziness or lightheadedness, rapid weight gain, swelling of your arms or legs. These may be signs of a condition called differentiation syndrome (see section 4 – Possible side effects). Differentiation

syndrome can happen any time during the first 3 months of Xospata treatment from as early as 1 day after starting treatment. If it occurs, your doctor will monitor you and may give you a medicine to treat your condition. She or he may also pause Xospata treatment until symptoms are reduced. You will also find this information in the Patient Alert Card that is included in the packaging. It is important that you keep this Alert Card with you and show it to any healthcare professional you see.

- if you have a seizure or quickly worsening symptoms such as headache, decreased alertness, confusion, blurred vision or other problems with seeing. These may be signs of a condition called PRES (see section 4. – Possible side effects). Your doctor may do a test to check if you have developed PRES and will stop Xospata treatment if it is confirmed that you have PRES.

Talk to your doctor, pharmacist or nurse before taking Xospata:

- if you have a heart rhythm disorder, such as an irregular heartbeat or a condition called QT prolongation (see section 4. – Possible side effects).
- if you have a history of low levels of the salts potassium or magnesium in your blood, as this may increase the risk of an abnormal heart rhythm.
- if you have severe pain in the upper abdomen and back, nausea and vomiting. These may be signs of an inflammation of the pancreas (pancreatitis).

### **Additional monitoring during treatment with Xospata**

Your doctor will carry out regular blood tests before and during treatment with Xospata. Your doctor will also regularly check your heart function before and during treatment.

### **Children and adolescents**

Do not give Xospata to children and adolescents under 18 years because it is not known whether it is safe and effective in this age group.

### **Other medicines and Xospata**

Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. Xospata may affect the way these medicines work, or these medicines may affect how Xospata works.

In particular, tell your doctor, pharmacist or nurse if you are taking any of the following medicines:

- medicines used to treat tuberculosis, such as rifampicin;
- medicines used to treat epilepsy, such as phenytoin;
- medicines used to treat fungal infections such as voriconazole, posaconazole or itraconazole;
- medicines used to treat bacterial infections such as erythromycin, clarithromycin or azithromycin;
- medicines used to treat high blood pressure (hypertension) such as captopril or carvedilol;
- medicines used to treat infections with the human immunodeficiency virus (HIV) such as ritonavir;
- medicines used to treat depression such as escitalopram, fluoxetine or sertraline;
- medicines used to treat heart problems, such as digoxin;
- medicines used to prevent blood clots, such as dabigatran etexilate;
- St. John's wort (also known as *Hypericum perforatum*), a herbal medicine used to treat depression.

If you normally take any of these medicines, your doctor might change it and prescribe a different medicine for you during your treatment with Xospata.

### **Pregnancy and breast-feeding**

Xospata may harm your unborn baby and should not be used during pregnancy. Women taking Xospata who are able to become pregnant should use an effective method of contraception during treatment with Xospata and for at least 6 months after stopping Xospata. If you use a hormonal contraceptive, you must also use a barrier method, such as a condom or a diaphragm. Men taking

Xospata whose partners are able to become pregnant should use an effective method of contraception during treatment with Xospata and for at least 4 months after stopping the treatment.

It is not known if Xospata passes into your breast milk and could harm your baby. You should not breast-feed during treatment with Xospata and for at least 2 months after stopping the treatment.

If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.

### **Driving and using machines**

You may feel dizzy after taking Xospata. If this happens, do not drive or use machines.

## **3. How to take Xospata**

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Xospata is taken by mouth as tablets.

Your doctor will tell you what dose of Xospata to take. The recommended dose is 120 mg (three tablets) once a day. Your doctor may decide to increase or lower your dose or temporarily interrupt treatment. Continue treatment at the dose prescribed by your doctor.

### **Taking Xospata**

- Take Xospata once a day at the same time each day.
- Swallow the tablets whole with water.
- Do not break or crush the tablets.
- Xospata can be taken with or without food.
- Continue taking Xospata for as long as your doctor tells you.

### **If you take more Xospata than you should**

If you take more tablets than you should, stop taking Xospata and contact your doctor.

### **If you forget to take Xospata**

If you forget to take Xospata at the usual time, take your usual dose as soon as you remember on the same day and take your next dose at the usual time on the following day. Do not take a double dose to make up for a forgotten dose.

### **If you stop taking Xospata**

Do not stop taking this medicine unless your doctor tells you to.

If you have any further questions on the use of this medicine, ask your doctor.

## **4. Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

### **Some possible side effects may be serious:**

- **Differentiation syndrome.** Contact your doctor straight away if you have any of the following symptoms: fever, trouble breathing, rash, dizziness or lightheadedness, rapid weight gain, swelling of your arms or legs. These may be signs of a condition called differentiation syndrome (may affect up to 1 in 10 people).
- **Posterior reversible encephalopathy syndrome (PRES).** Contact your doctor straight away if you have a seizure, quickly worsening headache, confusion, or other vision problems. There have been uncommon reports of a condition involving the brain, in patients treated with Xospata, called PRES (may affect up to 1 in 100 people).

- **Heart rhythm problems (QT prolongation).** Contact your doctor straight away if you have a change in your heartbeat, or if you feel dizzy, lightheaded, or faint. Xospata may cause a heart problem called QT prolongation (may affect up to 1 in 10 people).

### **Other possible side effects**

#### **Very common (may affect more than 1 in 10 people):**

- diarrhoea
- nausea
- constipation
- tiredness
- swelling due to fluid retention (oedema)
- loss of energy, weakness (asthenia)
- abnormal blood test results: high levels of blood creatine phosphokinase (indicative of muscle or heart function), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and/or blood alkaline phosphatase (indicative of liver function)
- pain in limbs
- joint pain (arthralgia)
- muscle pain (myalgia)
- cough
- shortness of breath (dyspnoea)
- dizziness
- low blood pressure (hypotension)

#### **Common (may affect up to 1 in 10 people):**

- collection of fluid around the heart, which, if severe, can decrease the heart's ability to pump blood (pericardial effusion)
- a vague feeling of discomfort, feeling unwell (malaise)
- a severe life-threatening allergic reaction, e.g., swelling in the mouth, tongue, face and throat, itching, hives (anaphylactic reaction)
- muscle stiffness
- passing less urine, swelling in the legs (signs of sudden kidney injury)
- inflammation of the heart (pericarditis)
- heart failure

### **Reporting of side effects**

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

### **5. How to store Xospata**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. The expiry date refers to the last day of that month.

Store in the original package in order to protect from light.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

## 6. Contents of the pack and other information

### What Xospata contains

- The active substance is gilteritinib. Each film-coated tablet contains 40 mg gilteritinib (as fumarate).
- The other ingredients are: mannitol (E421), hydroxypropylcellulose, low-substituted hydroxypropylcellulose, magnesium stearate, hypromellose, talc, macrogol, titanium dioxide, iron oxide yellow (E172).

### What Xospata looks like and contents of the pack

Xospata 40 mg film-coated tablets are round, light yellow film-coated tablets with the company logo and '235' debossed on one side of the tablet.

The tablets are provided in blisters and are available in packs containing 84 film-coated tablets (4-blisters of 21 film-coated tablets).

### Marketing Authorisation Holder and Manufacturer

Astellas Pharma Europe B.V.  
Sylviusweg 62  
2333 BE Leiden  
The Netherlands

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

#### **België/Belgique/Belgien**

Astellas Pharma B.V. Branch  
Tél/Tel: +32 (0)2 5580710

#### **Lietuva**

Biocodex UAB  
Tel.: +370 37 408 681

#### **България**

Астелас Фарма ЕООД  
Тел.: +359 2 862 53 72

#### **Luxembourg/Luxemburg**

Astellas Pharma B.V. Branch  
Belgique/Belgien  
Tél/Tel: +32 (0)2 5580710

#### **Česká republika**

Astellas Pharma s.r.o.  
Tel: +420 221 401 500

#### **Magyarország**

Astellas Pharma Kft.  
Tel.: +36 1 577 8200

#### **Danmark**

Astellas Pharma a/s  
Tlf: +45 43 430355

#### **Malta**

Astellas Pharmaceuticals AEBE  
Tel: +30 210 8189900

#### **Deutschland**

Astellas Pharma GmbH  
Tel.: +49 (0)89 454401

#### **Nederland**

Astellas Pharma B.V.  
Tel: +31 (0)71 5455745

#### **Eesti**

Biocodex OÜ  
Tel: +372 6 056 014

#### **Norge**

Astellas Pharma  
Tlf: +47 66 76 46 00

#### **Ελλάδα**

Astellas Pharmaceuticals AEBE  
Τηλ: +30 210 8189900

#### **Österreich**

Astellas Pharma Ges.m.b.H.  
Tel.: +43 (0)1 8772668

#### **España**

Astellas Pharma S.A.  
Tel: +34 91 4952700

#### **Polska**

Astellas Pharma Sp.z.o.o.  
Tel.: +48 225451 111

#### **France**

#### **Portugal**

Astellas Pharma S.A.S.  
Tél: +33 (0)1 55917500

**Hrvatska**

Astellas d.o.o  
Tel: +385 1670 0102

**Ireland**

Astellas Pharma Co. Ltd.  
Tel: +353 (0)1 4671555

**Ísland**

Vistor hf  
Sími: +354 535 7000

**Italia**

Astellas Pharma S.p.A.  
Tel: +39 (0)2 921381

**Κύπρος**

Ελλάδα  
Astellas Pharmaceuticals AEBE  
Τηλ: +30 210 8189900

**Latvija**

Biocodex SIA  
Tel: +371 67 619365

Astellas Farma, Lda.  
Tel: +351 21 4401320

**România**

S.C.Astellas Pharma SRL  
Tel: +40 (0)21 361 04 95/96/92

**Slovenija**

Astellas Pharma d.o.o  
Tel: +386 14011400

**Slovenská republika**

Astellas Pharma s.r.o.  
Tel: +421 2 4444 2157

**Suomi/Finland**

Astellas Pharma  
Puh/Tel: +358 (0)9 85606000

**Sverige**

Astellas Pharma AB  
Tel: +46 (0)40-650 15 00

**United Kingdom (Northern Ireland)**

Astellas Pharma Co., Limited  
Tel: +353 (0)1 4671555  
Free call from Northern Ireland: 0800 783 5018

**This leaflet was last revised in MM/YYYY**

Detailed information on this medicine is available on the European Medicines Agency web site:  
<http://www.ema.europa.eu>